



PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 40539

Title: Adiponectin as a novel biomarker for liver fibrosis

Reviewer’s code: 02540709

Reviewer’s country: Spain

Science editor: Fang-Fang Ji

Date sent for review: 2018-07-02

Date reviewed: 2018-07-08

Review time: 6 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer’s expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

I have read with deep interest the minireview “Adiponectin as a novel biomarker for liver fibrosis” by Udomsinprasert W et al. This is an interesting and comprehensive update about the role of adiponectin in liver fibrosis. The protective role of adiponectin in liver fibrosis has been widely described by several authors and, as



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

updated in this review, different approaches to increase the adiponectin concentrations have been investigated. But on the contrary, a few studies have reported that increased plasma level of adiponectin correlates with liver fibrosis progression in different chronic liver diseases. In order to improve the manuscript, authors might discuss briefly the postulated hypothesis about these contradictory findings. Why the adiponectin levels are increased in liver fibrosis?, Is there any problem with adiponectin receptors or signaling in patients with chronic liver diseases?

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No



PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 40539

Title: Adiponectin as a novel biomarker for liver fibrosis

Reviewer’s code: 03259763

Reviewer’s country: Germany

Science editor: Fang-Fang Ji

Date sent for review: 2018-07-02

Date reviewed: 2018-07-08

Review time: 6 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer’s expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Udomsinprasert and Colleagues conducted a Minireview on adiponectin in chronic liver diseases and fibrosis. Overall the manscript ist written well, and the topic is of interest. Is there any data on adiponectin in acute liver failure? More in-depth discussion of environmental factors contributing to chronic liver diseases and fibrosis, such as alcohol



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

(specific substances within alcohol), viral hepatitis, toxins (which?) and interaction with adiponectin would be of interest. More details on genes coding for adiponectin would be welcome, are there any functionally relevant polymorphisms known? The statement: "It is noteworthy that a physiological level of circulating adiponectin is important for defense against metabolic disorders and may be related to other chronic diseases" (p. 6, line 23) should be backup up by further references Discussion: As there only data availabe from small clincial studies, statements in the conclusions should be tempered down. It also seems to be of interest to include in the discussion, that the development of anti-fibrotic therapies in fibrosis/cirrhosis has been largely not successfull yet. p. 11, line 16: "Chief endpoints" : consider alternative terminology

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No



PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 40539

Title: Adiponectin as a novel biomarker for liver fibrosis

Reviewer’s code: 03646970

Reviewer’s country: United States

Science editor: Fang-Fang Ji

Date sent for review: 2018-07-02

Date reviewed: 2018-07-10

Review time: 7 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	(General priority)	Peer-reviewer’s expertise on the topic of the manuscript:
<input type="checkbox"/> Grade E: Do not publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Minor revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> General
		<input type="checkbox"/> Rejection	<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Reviewers Comments This is a review article summarizing current knowledge regarding role of adeponectin in development of hepatic fibrosis and it's potential as a non-invasive marker for liver fibrosis. overall the manuscript is well written and free of errors. There are minor issues that need to be addressed including description of method



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

for literature search and basis for inclusion or exclusion. Major Revision Comment: The authors should describe their method for literature review. The authors describe this as an exciting new field however the most recent study included in this table is from 2015. There is one study each from 2012 and 2013 and remaining studies are from 2011 and older. Please include more recent studies if available. Minor revisions 1. Page 6 last line The adipoR1 binds globular adiponectin with a high-affinity receptor and full-length adiponectin with a low-affinity receptor, whereas adipoR2 has an intermediate affinity for both isoforms. Comment: Please clarify. Does the author mean to say that adipoR1 binds globular adiponectin with high affinity and full length adiponectin with low affinity or are they suggesting that there are two isoforms of the adipoR1 (high affinity vs low affinity) 2. Page 9 last paragraph SMAD4 Comment: Kindly use complete form followed by abbreviation in brackets, given that this is the first instance of this acronym in the manuscript

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- [Y] No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- [Y] No